Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.

Krisp C, Randall SA, McKay MJ, Molloy MP.

Proteomics Clin Appl. 2012 Jan;6(1-2):42-59. doi: 10.1002/prca.201100062. Epub 2011 Dec 27. Review.

PMID:
22213646
2.

Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis.

Chiu CL, Randall S, Molloy MP.

Bioanalysis. 2009 Jul;1(4):847-55. doi: 10.4155/bio.09.56. Review.

PMID:
21083142
3.

Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.

Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.

J Proteome Res. 2011 Jan 7;10(1):133-42. doi: 10.1021/pr100153j. Epub 2010 Jun 4.

PMID:
20499897
4.

Biomarker validation in blood specimens by selected reaction monitoring mass spectrometry of N-glycosites.

Ossola R, Schiess R, Picotti P, Rinner O, Reiter L, Aebersold R.

Methods Mol Biol. 2011;728:179-94. doi: 10.1007/978-1-61779-068-3_11.

PMID:
21468948
5.

How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease.

Puntmann VO.

Postgrad Med J. 2009 Oct;85(1008):538-45. doi: 10.1136/pgmj.2008.073759. Review.

PMID:
19789193
6.

Multidimensional protein identification technology-selected reaction monitoring improving detection and quantification for protein biomarker studies.

Krisp C, McKay MJ, Wolters DA, Molloy MP.

Anal Chem. 2012 Feb 7;84(3):1592-600. doi: 10.1021/ac2028485. Epub 2012 Jan 24.

PMID:
22224914
7.

On the development of plasma protein biomarkers.

Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R.

J Proteome Res. 2011 Jan 7;10(1):5-16. doi: 10.1021/pr1008515. Epub 2010 Dec 13. Review.

PMID:
21142170
8.

Endothelial cell biology and pathology.

Dejana E, Simionescu M, Wolburg H.

Cell Tissue Res. 2009 Jan;335(1):1-3. doi: 10.1007/s00441-008-0697-2. No abstract available.

PMID:
19015887
9.

Computational biology for cardiovascular biomarker discovery.

Azuaje F, Devaux Y, Wagner D.

Brief Bioinform. 2009 Jul;10(4):367-77. doi: 10.1093/bib/bbp008. Epub 2009 Mar 10.

PMID:
19276200
10.

The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases.

Gianazza E, Tremoli E, Banfi C.

Expert Rev Proteomics. 2014 Dec;11(6):771-88. doi: 10.1586/14789450.2014.947966. Epub 2014 Sep 2. Review.

PMID:
25400095
11.

Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?

Fichtlscherer S, Zeiher AM, Dimmeler S.

Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2383-90. doi: 10.1161/ATVBAHA.111.226696. Review.

12.

Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation.

Percy AJ, Byrns S, Chambers AG, Borchers CH.

Expert Rev Proteomics. 2013 Dec;10(6):567-78. doi: 10.1586/14789450.2013.856763. Review. Erratum in: Expert Rev Proteomics. 2015 Feb;12(1):109. Expert Rev Proteomics. 2015 Feb;12(1):109.

PMID:
24206229
13.
14.

Strategies for plasma proteomic profiling of cancers.

Omenn GS.

Proteomics. 2006 Oct;6(20):5662-73. Review.

15.

Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Rifai N, Gillette MA, Carr SA.

Nat Biotechnol. 2006 Aug;24(8):971-83. Review.

PMID:
16900146
16.

Imaging and laboratory biomarkers in cardiovascular disease.

Andreassi MG, Gastaldelli A, Clerico A, Salvadori PA, Sicari R, Picano E.

Curr Pharm Des. 2009;15(10):1131-41. Review.

PMID:
19355954
17.

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB.

J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28.

18.

Systems approach to neurodegenerative disease biomarker discovery.

Lausted C, Lee I, Zhou Y, Qin S, Sung J, Price ND, Hood L, Wang K.

Annu Rev Pharmacol Toxicol. 2014;54:457-81. doi: 10.1146/annurev-pharmtox-011613-135928. Epub 2013 Oct 23. Review.

PMID:
24160693
19.

Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities.

Sattar N.

Diabet Med. 2012 Jan;29(1):5-13. doi: 10.1111/j.1464-5491.2011.03480.x. Review.

PMID:
21988593
20.

The role of genetics for biomarker development in neurodegeneration.

Bertram L, Hampel H.

Prog Neurobiol. 2011 Dec;95(4):501-4. doi: 10.1016/j.pneurobio.2011.09.011. Epub 2011 Oct 12.

PMID:
22005514

Supplemental Content

Support Center